LPA rs2149956: What Your Genotype Means
The rs2149956 variant is a genetic marker located within the LPA gene, which is responsible for producing apolipoprotein(a). This variant is studied for its potential associations with circulating lipoprotein(a) levels and its influence on cardiovascular health and long-term wellness.
What each genotype means
Typical lipoprotein(a) profile
This genotype represents the most common configuration for this variant in many populations. Research indicates that individuals with this profile generally do not carry the specific genetic signal associated with elevated lipoprotein(a) levels linked to this locus. Please note that lipoprotein(a) levels are influenced by multiple genetic and environmental factors, so this result should be interpreted in the context of your overall cardiovascular health profile.
Carried by the majority of individuals in most global populations.
Potential for altered lipoprotein(a)
Carrying one copy of the T allele may be associated with variations in circulating lipoprotein(a) levels compared to those without it. While some studies link variants in the LPA gene to cardiovascular health markers, the evidence for this specific variant's individual impact is limited and may vary significantly based on your ancestral background. Discuss your cardiovascular risk factors and any concerns about lipid levels with your healthcare provider.
Carried by roughly 1 in 6 people of European ancestry; less common in East Asian populations.
Increased lipoprotein(a) association
This genotype is associated with a higher likelihood of elevated lipoprotein(a) levels in some research cohorts. Elevated lipoprotein(a) is considered a potential risk factor for cardiovascular health, though the clinical significance of this specific genotype remains a subject of ongoing study. You should discuss your lipid profile and cardiovascular health history with a clinician to determine if further screening or management is appropriate.
This genotype is relatively rare, occurring in a small percentage of the European population and even less frequently in other ancestral groups.
Understanding the rs2149956 Variant
The rs2149956 variant is a single-nucleotide polymorphism (SNP) situated within the LPA gene locus. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. The LPA gene is located on chromosome 6 and provides the instructions for creating apolipoprotein(a), a key component of lipoprotein(a). Because this variant sits within a region known to influence the expression and structure of this protein, researchers monitor it to understand how subtle changes in DNA sequence might correlate with physiological differences in lipid metabolism. While the variant is identified by its specific rsID, it is part of a complex genetic landscape within the LPA gene that collectively determines how much lipoprotein(a) an individual produces.
The Role of the LPA Gene
The LPA gene is essential for the synthesis of lipoprotein(a), a complex particle in the blood that consists of an LDL-like particle linked to a specific protein called apolipoprotein(a). Lipoprotein(a) levels are primarily determined by genetics, and the LPA gene is the most significant contributor to these concentrations. High levels of circulating lipoprotein(a) are widely recognized as an independent risk factor for cardiovascular conditions. The gene's structure is unique, containing multiple copies of a sequence called kringle IV, which can vary in number between individuals. This structural variation, combined with SNPs like rs2149956, influences the rate at which the liver produces and clears these particles from the bloodstream, thereby impacting overall cardiovascular health profiles.
Research and Evidence Strength
Current research into rs2149956 is categorized as having limited evidence regarding its direct impact on health outcomes. While the LPA gene is definitively linked to cardiovascular risk, the specific contribution of the rs2149956 variant is still being characterized. Many studies utilize Mendelian randomization to determine if genetic variants are causally linked to disease, but findings for individual SNPs can be nuanced. The evidence suggests that while this variant may be associated with variations in lipoprotein(a) levels, it does not act in isolation. Because cardiovascular health is influenced by a combination of genetics, lifestyle, and environment, the predictive power of a single SNP like rs2149956 remains a subject of ongoing scientific investigation rather than a definitive diagnostic tool.
Population Frequency and Interpretation
Genetic variants are distributed differently across global populations, and rs2149956 is no exception. In European populations, the minor allele frequency for this variant is approximately 0.08, meaning it is present but not the most common form of the gene in that group. Understanding these frequencies is vital for researchers to ensure that genetic studies are representative of diverse ancestries. When interpreting this information, it is important to remember that having a specific genotype does not guarantee a particular health outcome. Genetic data provides a snapshot of biological predisposition, but it does not account for the complex interplay of diet, exercise, and medical history that ultimately shapes an individual's healthspan.
Navigating Genetic Information
If you have received information about your rs2149956 genotype, it is important to view it as one small piece of a much larger puzzle. This information is educational and should not be used to diagnose or treat any condition. Because the LPA gene is involved in cardiovascular health, individuals interested in their lipid profiles should consult with a healthcare provider or a cardiologist. They can interpret your results in the context of your overall health, including blood tests for cholesterol and lipoprotein(a) levels. If you are currently taking medications to manage cardiovascular risk, never make changes to your dosage or treatment plan based on genetic reports without first discussing these findings with your clinician or pharmacist.
How common is this variant?
The minor allele frequency for rs2149956 is approximately 0.08 in European populations, indicating that the variant is relatively uncommon.
Frequently asked questions
What does the LPA gene do?
The LPA gene provides instructions for making apolipoprotein(a), which is a protein component of lipoprotein(a). Lipoprotein(a) is a type of cholesterol-carrying particle in the blood.
Is rs2149956 a cause of heart disease?
The rs2149956 variant is associated with lipoprotein(a) levels, which are a known risk factor for cardiovascular disease. However, it is not a direct cause of heart disease, and its individual impact is considered limited.
Should I be worried about my rs2149956 result?
Genetic results are not medical diagnoses. You should discuss your results with a healthcare professional who can evaluate your overall cardiovascular risk factors, such as blood pressure and lipid panels.
Can I change my risk associated with this variant?
While you cannot change your DNA, you can manage your cardiovascular health through lifestyle choices like diet and exercise. Always consult your doctor before making changes to your health management plan.
Sources & further reading
Educational information only, last refreshed 9/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2149956?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in LPA
This variant in the LPA gene elevates serum lipoprotein(a) levels, significantly increasing the risk of coronary atherosclerosis and aortic stenosis.
Intronic splice-affecting variant in LPA leading to elevated plasma lipoprotein(a) concentrations and increased risk of aortic valve stenosis and coronary disease.
A splice-altering variant in LPA that lowers circulating lipoprotein(a) levels and is significantly associated with extended parental attained age and healthspan.
Intronic variant in LPA strongly associated with elevated circulating lipoprotein(a) levels and increased risk for coronary artery disease and aortic stenosis.
This variant is strongly associated with significantly elevated levels of Lipoprotein(a), a major independent risk factor for heart disease.
An LPA-locus variant identified as an independent genetic determinant of human healthspan and disease-free survival through modulated cardiovascular risk.